SCHEMBL24664300

SCHEMBL24664300

CC(C)n1cc(-c2nc(Nc3cccc(N4CCN(C)CC4)c3)ncc2F)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 8/20 0.59
▸ CCNT1 O60563 7/20 0.59
▸ CDK9 P50750 7/20 0.59
▸ CCNA2 P20248 6/20 0.59
▸ CDK1 P06493 4/20 0.59
▸ CCNB1 P14635 4/20 0.59
▸ CDK7 P50613 3/20 0.59
▸ CCNH P51946 3/20 0.59
▸ JAK2 O60674 9/20 0.59
▸ FLT3 P36888 9/20 0.59
▸ CSF1R P07333 2/20 0.53
▸ CCNE2 O96020 2/20 0.53
▸ CCNE1 P24864 2/20 0.53
▸ CCNB2 O95067 1/20 0.53
▸ CDK5 Q00535 1/20 0.53
▸ CDK5R1 Q15078 1/20 0.53
▸ CCNB3 Q8WWL7 1/20 0.53
▸ JAK1 P23458 1/20 0.51
▸ JAK3 P52333 1/20 0.51
▸ CDK4 P11802 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24664303 0.89 CSF1R (0.63) CDK2CCNT1CDK9CCNA2CDK1
SCHEMBL29608982 0.86 CDK6 (0.67) CDK2CCNA2JAK2FLT3CSF1R
SCHEMBL29606969 0.86 EGFR (0.55) CCNA2CDK1JAK2FLT3CSF1R
SCHEMBL24664426 0.86 CDK6 (0.67) CDK2CCNA2JAK2FLT3CSF1R
SCHEMBL24664306 0.86 EGFR (0.55) CCNA2CDK1JAK2FLT3CSF1R
SCHEMBL29608987 0.82 FLT3 (0.59) JAK2FLT3CSF1RJAK1JAK3
SCHEMBL24664432 0.82 FLT3 (0.59) JAK2FLT3CSF1RJAK1JAK3
SCHEMBL24664372 0.81 CSF1R (0.55) CDK2CCNT1CDK9CCNA2CDK1
SCHEMBL24664433 0.79 JAK2 (0.75) JAK2FLT3CSF1RJAK1JAK3
SCHEMBL29608225 0.79 JAK2 (0.75) JAK2FLT3CSF1RJAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114423750-B 2, 4-Disubstituted pyrimidine derivative, preparation method and application thereof 成都赜灵生物医药科技有限公司 2024-04-19 — — CN disclosed
US-20220298140-A1 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) 2022-09-22 — — US disclosed
CN-114423750-A 2, 4-disubstituted pyrimidine derivative and preparation method and application thereof 成都赜灵生物医药科技有限公司 2022-04-29 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298140-A1 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF JAK2, FLT3, JAK1 CDK2 9/4885CCNT1 263/4885CDK9 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback